Bioperfectus Digital Press Conference for AACC 2020

Company news
2020-12-11

BioPerfectus, a public listed company at Shanghai Stock Exchange (SSE:688399), is one of the leading molecular diagnostic solution manufacturer in global in-vitro diagnostics market since 2010. 

With headquarter located in Taizhou, branch offices sited in Shanghai, Xi’an and Beijing, Bioperfectus is pioneering in molecular diagnostics market with our products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices etc...

Since the inception of International Sales and Marketing Division in June, 2020, under the authorization of international renowned public health organizations and institutions, our products have been being distributed in over 50 countries all over the world and about to come to cover more countries in the near future.

Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream to create a healthier future for our next generations.

In the coming year of 2021, we are going to launch more and more high-quality and cost-efficient IVD solution products to the world and there will be more product pipelines coming including STD, Vector-borne and so on.

To Let us look forward to a healthier and better future!

Join us at Bioperfectus Digital Press Conference to know more!

Join Zoom Meeting Link:https://zoom.com.cn/j/84949574333pwd=eHBhUlQrM01EazVXNkU0UDBOYkorUT09

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14